Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
inclusion~Women may be included in the study if they meet all of the following criteria:~* in good general health~* age 18 to 40 years, inclusive~* willing to provide informed consent and follow all study requirements~* not pregnant~* does not desire to become pregnant in the next 24 months~* regular menstrual cycle (24 to 35 days)~* confirmed ovulation by serum P ≥ 4.7 ng/mL in two consecutive samples during the pre-treatment phase of the study~* at low risk of pregnancy (e.g., sterilized, in exclusively same sex partnership, in monogamous relationship with vasectomized partner, abstinent, using non-hormonal IUD or condoms)~* has a body mass index of 18.0 to 35.0~* has hemoglobin ≥10.5 g/L~exclusion~Women will be excluded from participating in this study if they meet any of the following criteria:~* medical contraindications to DMPA use~* use of any of the following medications within 1 month prior to enrollment:~  * any investigational drug~ * prohibited drugs (per protocol)~ * oral contraceptives~ * LNG IUS or implant~* use of DMPA in the past 12 months~* use of a combined injectable contraceptive in the past 6 months~* recent pregnancy (within 3 months)~* current lactation~* ongoing or anticipated use of prohibited drugs (per protocol)~* known sensitivity to MPA~* plan to move to another location in the next 18 months~* any condition (social or medical) which in the opinion of the site investigator would make study participation unsafe, would interfere with adherence to study requirements or complicate data interpretation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- DMPA 150 (Type: EXPERIMENTAL): single subcutaneous injection of 150mg/mL of DMPA in the abdomen
- DMPA 300 (Type: EXPERIMENTAL): single subcutaneous injection of 300mg/2mL of DMPA in the abdomen
- DMPA 104 (Type: ACTIVE_COMPARATOR): two injections, given at three months intervals, of 104mg/0.65mL of DMPA in the abdomen

Based on this trial design, predict the completion outcome and termination type (if applicable).